TROP-2 in NSCLC

CME

Antibody‒Drug Conjugates Targeting TROP-2 in NSCLC: A Look to the Future

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: July 25, 2023

Expiration: July 24, 2024

Activity

Progress
1
Course Completed

References

  1. Ado-trastuzumab emtansine [prescribing information]. South San Francisco, CA: Genentech; 2022.
  2. Fam-trastuzumab deruxtecan-nxki [prescribing information]. Basking Ridge, NJ: Daiichi Sankyo; 2022.
  3. Drago JZ, Modi S, Chandarlapaty S. Unlocking the potential of antibody-drug conjugates for cancer therapy. Nat Rev Clin Oncol. 2021;18:327-344.
  4. Nakada T, Sugihara K, Jikoh T, et al. The latest research and development into the antibody-drug conjugate, [fam-] trastuzumab deruxtecan (DS-8201a), for HER2 cancer therapy. Chem Pharm Bull (Tokyo). 2019;67:173-185.
  5. Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387:9-20.
  6. Shvartsur A, Bonavida B. Trop2 and its overexpression in cancers: regulation and clinical/therapeutic implications. Genes Cancer. 2015;6:84-105.
  7. Lenárt S, Lenárt P, Šmarda J, et al. Trop2: jack of all trades, master of none. Cancers (Basel). 2020;12:3328.
  8. Lin JC, Wu YY, Wu JY, et al. TROP2 is epigenetically inactivated and modulates IGF-1R signalling in lung adenocarcinoma. EMBO Mol Med. 2012;4:472-485.
  9. Jiang A, Gao X, Zhang D, et al. Expression and clinical significance of the Trop-2 gene in advanced non-small cell lung carcinoma. Oncol Lett. 2013;6:375-380.
  10. Inamura K, Yokouchi Y, Kobayashi M, et al. Association of tumor TROP2 expression with prognosis varies among lung cancer subtypes. Oncotarget. 2017;8:28725-28735.
  11. Mito R, Matsubara E, Komohara Y, et al. Clinical impact of TROP2 in non-small lung cancers and its correlation with abnormal p53 nuclear accumulation. Pathol Int. 2020;70:287-294.
  12. Goldenberg DM, Sharkey RM. Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: a case study of anti-TROP-2 sacituzumab govitecan-hziy. MAbs. 2019;11:987-995.
  13. Sacituzumab govitecan-hziy [prescribing information]. Foster City, CA: Gilead Sciences; 2023.
  14. Okajima D, Yasuda S, Maejima T, et al. Datopotamab deruxtecan, a novel TROP2-directed antibody-drug conjugate, demonstrates potent antitumor activity by efficient drug delivery to tumor cells. Mol Cancer Ther. 2021;20:2329-2340.
  15. Li BT, Michelini F, Misale S, et al. HER2-mediated internalization of cytotoxic agents in ERBB2 amplified or mutant lung cancers. Cancer Discov. 2020;10:674-687.
  16. Koyama K, Ishikawa H, Abe M, et al. Patritumab deruxtecan (HER3-DXd), a novel HER3 directed antibody drug conjugate, exhibits in vitro activity against breast cancer cells expressing HER3 mutations with and without HER2 overexpression. PLoS One. 2022;17:e0267027.
  17. Verma S, Breadner D, Raphael J. Targeting improved outcomes with antibody-drug conjugates in non-small cell lung cancer-an updated review. Curr Oncol. 2023;30:4329-4350.
  18. Spitaleri G, Aliaga P, Attili I, et al. Sustained improvement in the management of patients with non-small-cell lung cancer (NSCLC) harboring ALK translocation: where are we running? Curr Oncol. 2023;30:5072-5092.
  19. Bardia A, Messersmith WA, Kio EA, et al. Sacituzumab govitecan-hziy, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial. Ann Oncol. 2021;32:746-756.
  20. Heist RS, Guarino MJ, Masters G, et al. Therapy of advanced non-small-cell lung cancer with an SN-38-anti-Trop-2 drug conjugate, sacituzumab govitecan-hziy. J Clin Oncol. 2017;35:2790-2797.
  21. Shimizu T, Sands J, Yoh K, et al. First in-human, phase I dose-escalation and dose-expansion study of trophoblast cell-surface antigen 2-directed antibody-drug conjugate datopotamab deruxtecan in non-small-cell lung cancer: TROPION-PanTumor01. J Clin Oncol. 2023;[Epub ahead of print].
  22. Levy B, Paz-Ares L, Rixe O, et al. TROPION-Lung02: initial results for datopotamab deruxtecan plus pembrolizumab and platinum chemotherapy in advanced NSCLC. Presented at: 2022 International Association for the Study of Lung Cancer World Conference on Lung Cancer; August 6-9, 2022. Abstract MA13.07.
  23. Goto Y, Su WC, Philip B, et al. TROPION-Lung02: datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) in advanced non-small cell lung cancer (aNSCLC). Presented at: 2023 American Society of Clinical Oncology Annual Meeting; June 2-6, 2023. Abstract 9004.
  24. Pérez-García JM, Vaz Batista M, Cortez P, et al. Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial. Neuro Oncol. 2023;25:157-166.
  25. Forde PM, Spicer J, Lu S, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 2022;386:1973-1985.
  26. Garon E, Johnson M, Lisberg A, et al. Efficacy of datopotamab deruxtecan (Dato-DXd) in patients (pts) with advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC) and actionable genomic alterations (AGAs): preliminary results from the phase I TROPION-PanTumor01 study. Presented at: 2021 European Society for Medical Oncology Congress; September 16-21, 2021. Abstract LBA49.
  27. Ludmir EB, Mainwaring W, Lin TA, et al. Factors associated with age disparities among cancer clinical trial participants. JAMA Oncol. 2019;5:1769-1773.
  28. Oyer RA, Hurley P, Boehmer L, et al. Increasing racial and ethnic diversity in cancer clinical trials: an American Society of Clinical Oncology and Association of Community Cancer Centers Joint Research Statement. J Clin Oncol. 2022;40:2163-2171.